
## **Carolin Ludwig**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9709465/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Science Immunology, 2021, 6, eabj1031.	11.9	223
2	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2021, 32, 3027-3033.	6.1	82
3	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients. JCI Insight, 2022, 7, .	5.0	62
4	B Cell Numbers Predict Humoral and Cellular Response Upon <scp>SARS</scp> – <scp>CoV</scp> â€2 Vaccination Among Patients Treated With Rituximab. Arthritis and Rheumatology, 2022, 74, 934-947.	5.6	55
5	Robust and durable serological response following pediatric SARS-CoV-2 infection. Nature Communications, 2022, 13, 128.	12.8	54
6	Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. Journal of Infectious Diseases, 2021, 223, 796-801.	4.0	51
7	mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. Vaccines, 2021, 9, 918.	4.4	40
8	Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors. Journal of Immunology, 2021, 206, 2614-2622.	0.8	22
9	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Frontiers in Immunology, 2021, 12, 743422.	4.8	10
10	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients. Frontiers in Immunology, 2022, 13, 822885.	4.8	7
11	Erytra blood group analyser and kode technology testing of SARSâ€CoVâ€2 antibodies among convalescent patients and vaccinated individuals. EJHaem, 2022, 3, 72-79.	1.0	4
12	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Frontiers in Immunology, 0, 13, .	4.8	4